ROCKAWAY, N.J., Sept. 30, 2025 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced the publication of a peer-reviewed study in Frontiers in Neurology demonstrating the effectiveness of gammaCore® non-invasive vagus nerve stimulation (nVNS) in reducing persistent symptoms associated with mild traumatic brain injury (mTBI). “The CDC reports approximately 2.5 million emergency department visits each year in the United States for ...

ROCKAWAY, N.J., Sept. 29, 2025 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced that gammaCore™ Sapphire (nVNS) has been included in a long-term reimbursement policy launched by the National Institute for Health and Disability Insurance (RIZIV / INAMI) in Belgium. Effective October 1, 2025, the policy provides coverage for gammaCore Sapphire to treat patients with cluster headaches. This coverage is based on strong clinical ...

Company Leadership Changes - Peter Cuneo has departed from the Board of Directors of electroCore, Inc., with Thomas J. Errico, MD, elected as the new Chairman of the Board effective September 2, 2025 [1][2] - Cuneo will continue to serve as a strategic advisor to the company [1] - CEO Dan Goldberger expressed gratitude for Cuneo's contributions since 2020, highlighting his role in the company's turnaround [2] Company Overview - electroCore, Inc. is a commercial-stage bioelectronic technology company focused on improving health and quality of life through non-invasive bioelectronic technologies [3] - The company's leading products include gammaCore, a non-invasive vagus nerve stimulation device, and Quell neurostimulator, both aimed at treating chronic pain syndromes [3] - Additionally, electroCore markets handheld products like Truvaga and TAC-STIM, which utilize bioelectronic technologies for general wellness and human performance [3]

Core Insights - electroCore, Inc. has appointed Elena Bonfiglioli to its Board of Directors effective September 2, 2025, following the retirement of Peter Cuneo [1] - Ms. Bonfiglioli brings over two decades of experience in the healthcare sector, currently serving as Microsoft's Global Business Leader for Healthcare, Pharma Life Sciences, and International clinical applications [2] - She has been recognized as one of the top 50 AI Innovators and has held various leadership roles in healthcare organizations, emphasizing the use of data and AI to enhance health outcomes [2][3] Company Overview - electroCore, Inc. is a commercial-stage bioelectronic technology company focused on improving health and quality of life through non-invasive bioelectronic technologies [4] - The company's leading products include gammaCore, a non-invasive vagus nerve stimulation device, and Quell neurostimulator, both aimed at treating chronic pain syndromes [4] - Additionally, electroCore markets handheld products like Truvaga and TAC-STIM, which utilize bioelectronic technologies for general wellness and human performance [4]

Core Insights - electroCore, Inc. has appointed Kelly Benning as the Senior Vice President of Truvaga, effective July 21, 2025, bringing nearly 30 years of experience in digital health and consumer wellness [1][3] - Ms. Benning emphasizes the shift in the wellness market towards personalized, consumer-centric solutions, aiming to innovate and refine technology to empower individuals in managing their well-being [2][3] - The company focuses on building a movement around science-backed wellness solutions and plans to leverage strategic partnerships for greater accessibility to its consumer devices [2][3] Company Overview - electroCore is a commercial-stage bioelectronic technology company dedicated to improving health and quality of life through non-invasive bioelectronic technologies [5] - The company's leading products include gammaCore, a non-invasive vagus nerve stimulation device, and Quell neurostimulator, both targeting chronic pain syndromes [5] - electroCore also markets Truvaga™, a handheld device aimed at promoting general wellness and human performance [5] Leadership Background - Kelly Benning has a proven track record in bringing digital health products to market, including the first FDA-cleared watch for blood pressure monitoring [2][3] - Her previous roles include executive positions at LiveMetric, IBM Watson Health, and other healthcare enterprises, showcasing her extensive experience in the industry [3] - The CEO of electroCore, Dan Goldberger, expressed confidence in Ms. Benning's ability to expand the company's direct-to-consumer strategy [4]

Core Insights - electroCore, Inc. reported net sales of $7.4 million for Q2 2025, representing a 20% increase compared to Q2 2024, and year-to-date net sales of $14.1 million, a 22% increase compared to the first half of 2024 [4][8] - The company successfully closed the acquisition of NeuroMetrix, Inc. and completed the integration ahead of schedule, while also reducing cash usage to approximately $614,000 in Q2 2025 [3][8] Financial Performance - For Q2 2025, gross profit was $6.4 million, yielding an 87% gross margin, compared to $5.3 million and 86% gross margin in Q2 2024 [4] - Total operating expenses for Q2 2025 were approximately $9.9 million, up from $7.9 million in Q2 2024, driven by increased selling, general, and administrative expenses [6][9] - GAAP net loss for Q2 2025 was $3.7 million, or a loss of $0.44 per share, compared to a net loss of $2.7 million, or a loss of $0.38 per share, in Q2 2024 [11][22] Revenue Breakdown - The increase in net sales was primarily attributed to higher sales of prescription products sold to the U.S. Department of Veterans Affairs (VA) and growth in nonprescription wellness products, including Truvaga™ and TAC-STIM [4][8] - Prescription gammaCore sales to the VA increased by 13% year-over-year, while sales of Truvaga™ surged by 74% in Q2 2025 compared to Q2 2024 [5][8] Cash Position and Outlook - As of June 30, 2025, the company had cash, cash equivalents, restricted cash, and marketable securities totaling $7.4 million, down from $12.2 million at the end of 2024 [14] - For the full year 2025, the company expects total revenue to be approximately $30.0 million and net cash usage to be between $3.9 million and $4.4 million [15]

Company Overview - electroCore, Inc. is a commercial-stage bioelectronic technology company focused on improving health and quality of life through innovative non-invasive bioelectronic technologies [2] - The company's leading prescription products include gammaCore, a non-invasive vagus nerve stimulation (nVNS) device, and Quell neurostimulator, both aimed at treating chronic pain syndromes [2] - Additionally, electroCore offers Truvaga products, which are handheld nVNS devices designed for personal use to promote general wellness and human performance [2] Upcoming Financial Results - electroCore will report its financial results for the second quarter ended June 30, 2025, after the market closes on August 6, 2025 [1] - Management will host a webinar at 4:30 PM EDT on the same day to review the financial results and address investor questions [1] - Investors can access the webinar through a provided registration link and dial-in details [1]

Core Insights - electroCore, Inc. reported first quarter 2025 net sales of $6.7 million, a 23% increase compared to $5.4 million in the same period of 2024 [3][6] - The company closed the acquisition of NeuroMetrix, which is expected to enhance its position in the non-invasive bioelectronic technology market [2][6] - The CEO highlighted a 29% growth in total revenue excluding TAC-STIM, indicating strong performance in core product lines [2][6] Financial Performance - Gross profit for the first quarter of 2025 was $5.7 million, representing an 85% gross margin, compared to $4.6 million and 84% gross margin in the first quarter of 2024 [4][18] - Total operating expenses increased to approximately $9.5 million from $8.4 million in the first quarter of 2024, driven by higher selling, general, and administrative expenses [5][6] - The GAAP net loss for the first quarter of 2025 was $3.9 million, or a loss of $0.47 per share, compared to a net loss of $3.5 million, or a loss of $0.53 per share, in the first quarter of 2024 [8][18] Revenue Breakdown - Sales of prescription gammaCore to the U.S. Department of Veterans Affairs (VA) reached $4.7 million, a 22% increase from $3.9 million in the prior year [4] - International sales grew by 14%, with total sales outside the United States amounting to $513,000 [4] - Truvaga wellness products saw significant growth, with sales increasing by 187% to $1.1 million compared to $385,000 in the first quarter of 2024 [4] Guidance and Outlook - For the full year 2025, the company expects total revenue to be approximately $30 million, with net cash used for the next three quarters projected between $3.8 million and $4.3 million [12] - The acquisition of NeuroMetrix is anticipated to contribute meaningful revenue by the end of 2025, expanding the company's product offerings [12]

Core Insights - The merger between electroCore, Inc. and NeuroMetrix, Inc. has been completed, enhancing electroCore's position in the bioelectronic technology market focused on non-invasive health solutions [1][3] - The acquisition of NeuroMetrix's Quell® Fibromyalgia Solution expands electroCore's portfolio and is expected to significantly increase its addressable market for chronic pain and wellness treatments [2][3] Company Overview - electroCore, Inc. is a commercial-stage bioelectronic technology company dedicated to improving health and quality of life through innovative non-invasive technologies [5] - Following the merger, NeuroMetrix will become an indirect wholly-owned subsidiary of electroCore, with its shares being de-listed from the Nasdaq Capital Market [3][7] Market Position and Strategy - The merger allows electroCore to leverage established distribution channels, particularly within the VA Hospital System, to accelerate the adoption of the Quell Fibromyalgia solution [3] - The addition of the Quell solution diversifies electroCore's offerings in non-pharmaceutical, non-invasive nerve stimulation, reinforcing its leadership in the bioelectronic technology sector [3]

Core Insights - electroCore, Inc. announced that its flagship wellness product, Truvaga Plus, is now compatible with the Apple Health app, enhancing user experience and health management [1][2] - Truvaga Plus is a hand-held vagus nerve stimulator aimed at providing stress relief, improving sleep, enhancing peace of mind, and improving focus [1] - The integration with the Apple Health app allows users to track their health data, including their progress with Truvaga Plus, in a consolidated view [2] Product Features - Truvaga Plus enables users to log their feelings after each session, utilizing the State of Mind API to monitor mental wellbeing over time [2] - The Apple Health app provides a secure platform for users to store and access important health information, leveraging the privacy features of iPhones [3] Company Overview - electroCore, Inc. is a commercial-stage bioelectronic technology company focused on improving health and quality of life through innovative non-invasive technologies [4]